Thymic tumors and immune checkpoint inhibitors

Area of Science:

• Oncology
• Immunotherapy
• Thoracic Malignancies

Background:

• Thymoma and thymic carcinoma (thymic epithelial tumors, TETs) are thoracic malignancies with variable prognosis.
• Extensive tumor spread frequently precludes surgical resection, necessitating effective nonsurgical treatments.
• Current chemotherapeutic regimens for TETs lack established optimal protocols.

Purpose of the Study:

• To review the role of immunotherapy, specifically PD-1/PD-L1 inhibitors, as a therapeutic alternative for refractory TETs.
• To analyze the expression and significance of programmed death ligand 1 (PD-L1) and programmed death 1 (PD-1) in TETs.
• To identify the need for further research to optimize immunotherapeutic strategies for TETs.

Main Methods:

• Review of existing studies on PD-1 and PD-L1 expression in TETs.
• Analysis of clinical trial data regarding the efficacy and safety of PD-1 inhibitors in TETs.
• Evaluation of conflicting results due to variations in immunohistochemical methods and cutoff values.

Main Results:

• Conflicting data exists regarding PD-1/PD-L1 expression in TETs, influenced by antibody and cutoff variations.
• Abundant PD-L1 expression is frequently observed, suggesting potential as a predictive biomarker for immunotherapy.
• PD-1 inhibitors have demonstrated acceptable clinical efficacy in some trials, alongside concerns about immune-related adverse events.

Conclusions:

• Immunotherapy, particularly PD-1 inhibitors, presents a promising avenue for refractory thymic epithelial tumors.
• Further research is crucial to resolve conflicting findings on PD-1/PD-L1 expression and its prognostic significance.
• Optimizing immunotherapeutic drug availability and elucidating their mechanisms of action are urgently required for refractory TETs.